{"prompt": "['Amended Clinical Trial Protocol 03', '18-Oct-2019', 'EFC14153 - dupilumab', 'Version number: 1', 'PCSA:', 'Potentially clinically significant abnormality', 'PEF:', 'Peak expiratory flow', 'ppb:', 'Parts per billion', 'PROs:', 'Patient reported outcomes', 'PRQLQ-IA:', 'Pediatric Rhinoconjunctivitis Quality of Life Questionnaire - Interviewer', 'Administered', 'PT:', 'Preferred term', 'q2w:', 'Once every 2 weeks', 'q4w:', 'Once every 4 weeks', 'SAE:', 'serious adverse event', 'SAP:', 'Statistical analysis plan', 'SC:', 'Subcutaneous(ly', 'SCS:', 'Systemic corticosteroids', 'SD:', 'Standard deviation', 'SEM:', 'Standard error of the mean', 'SOC:', 'System Organ Class', 'TARC:', 'Thymus and Activation Regulated Chemokine', 'TBV:', 'Total blood volume', 'TEAEs:', 'Treatment-emergent adverse events', 'ULN:', 'Upper Limit of Normal', 'Property of the Sanofi Group - strictly confidential', 'Page 36', 'VV-CLIN-0528583 6.0']['Amended Clinical Trial Protocol 03', '18-Oct-2019', 'EFC14153 - dupilumab', 'Version number: 1', '4', 'INTRODUCTION AND RATIONALE', 'Asthma is a chronic inflammatory disease of the airways characterized by airway', 'hyperresponsiveness, acute and chronic bronchoconstriction, airway edema, and mucus plugging.', 'The inflammatory component of asthma involves many cell types, including mast cells,', 'eosinophils, T-lymphocytes, neutrophils, and epithelial cells and their biological products. For', 'most asthma patients, a regimen of controller therapy and reliever therapy provides adequate', 'long-term control.', 'The majority of children with asthma have mild or moderate disease and can obtain adequate', 'asthma control through avoidance of triggering factors and/or with the help of medications, such', 'as short-acting inhaled \u00df2-receptor agonists, inhaled corticosteroids (ICS) and, when needed,', 'addition of long-acting \u00df2-receptor agonists and leukotriene receptor antagonists (LTRA).', 'However, 2-5% of all asthmatic children have uncontrolled asthma despite maximum treatment', 'with conventional medications (2). Children with such severe symptoms are heterogeneous with', 'respect to trigger factors, pulmonary function, inflammatory pattern and clinical symptoms (3).', 'These children have a reduced quality of life, account for a large proportion of the healthcare costs', 'related to asthma and represent a continuous clinical challenge to the pediatrician.', 'Additionally, the long term adverse effects of systemic and ICS on bone metabolism, adrenal', 'function, and growth in children lead to attempts to minimize the amount of corticosteroid usage.', 'Lastly, the consequences of unresponsiveness to therapy or lack of compliance with therapy are', 'evidenced by loss of asthma control (LOAC), which can be severe (ie, severe asthma exacerbation', 'event) and possibly life-threatening. The poor response of some patients with asthma may reflect', 'the number of cellular and molecular mechanisms operative in asthma. There is increasing interest', 'in distinct phenotypes because targeted therapy is more likely to be successful in patients with', 'similar underlying pathobiologic features (4). Recent therapeutic approaches in asthma have been', 'focused on trying to control type 2 inflammation. A vast majority of 6-11 years old with asthma', 'show evidence of type 2 inflammation characterized by upregulation of inflammatory cytokines,', 'interleukin-4 (IL-4), interleukin-5 (IL-5), and interleukin-13 (IL-13). The most recent GINA', 'guidelines (1) for management of severe asthma report that for patients with severe asthma, type 2', 'inflammation can be identified by elevated peripheral eosinophils (150 cells/L) and/or elevated', 'FeNO (20 ppb), and/or sputum eosinophils 2%, and/or asthma that is clinically allergen-driven.', 'Up-regulation of IL-4 and IL-13 activity has been implicated as an important inflammatory', 'component of asthma disease progression. Dupilumab is under development as a potential novel', 'treatment for asthma. Dupilumab, a fully human monoclonal antibody, is directed against the IL-4', 'receptor alpha subunit (IL-4Ra), which is a component of IL-4 heterodimeric receptors Type I', '(IL4-ligand only) and Type II (both IL-4 and IL-13 ligands). The binding of dupilumab to IL-4Ra', 'results in blockade of downstream signaling initiated by both IL-4 and IL-13. For complete', 'information regarding the preclinical and clinical evaluation of dupilumab to date, see the', \"Investigator's Brochure.\", '4.1', 'RATIONALE', 'This is a Phase 3, randomized, double-blind, placebo-controlled efficacy and safety study to be', 'conducted in children 6 to <12 years of age with uncontrolled persistent asthma while on a', 'Property of the Sanofi Group - strictly confidential', 'Page 37', 'VV-CLIN-0528583 6.0']\n\n###\n\n", "completion": "END"}